Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.

Kourtney HolbrookJose LutzkyMichael A DaviesJessica Michaud DavisIsabella C GlitzaRodabe N AmariaAdi DiabSapna Pradyuman PatelAsim AminHussein Tawbi

Published in: Cancer (2019)

Combination therapy with encorafenib plus binimetinib elicited intracranial activity in patients with BRAF-mutant MBMs, including patients previously treated with BRAF/MEK inhibitors. Further prospective studies are warranted and ongoing.

Keyphrases

combination therapy
brain metastases
end stage renal disease
newly diagnosed
small cell lung cancer
ejection fraction
wild type
chronic kidney disease
prognostic factors
peritoneal dialysis
optic nerve
metastatic colorectal cancer
patient reported outcomes
cell proliferation
skin cancer
patient reported